Elizabeth DeVita-Raeburn is a New York-based writer who specializes in science, health and medicine. She is the author of The Death of Cancer and The Empty Room. She lives in New York City, with her husband, the writer Paul Raeburn, and two sons.
Elizabeth DeVita-Raeburn
From this contributor
The controversy over autism’s most common therapy
Applied behavioral analysis is the most widely used therapy for autism, but some people say its drills and routines are cruel, and its aims misguided.
The controversy over autism’s most common therapy
By
Elizabeth DeVita-Raeburn
10 August 2016 | 20 min read
Explore more from The Transmitter
‘Overdue’ debate unfurls over neuroimaging method
After a January paper questioned the validity of an approach called lesion network mapping, its users are pressure testing their results.
‘Overdue’ debate unfurls over neuroimaging method
After a January paper questioned the validity of an approach called lesion network mapping, its users are pressure testing their results.
By
Angie Voyles Askham
17 April 2026 | 8 min read
Nearly 400 compounds affect behaviors tied to autism-linked genes in zebrafish
Estropipate, paclitaxel and levocarnitine altered behaviors tied to SCN2A and DYRK1A variants specifically, a new open-source platform revealed.
Nearly 400 compounds affect behaviors tied to autism-linked genes in zebrafish
Estropipate, paclitaxel and levocarnitine altered behaviors tied to SCN2A and DYRK1A variants specifically, a new open-source platform revealed.
By
Charles Q. Choi
16 April 2026 | 4 min read
What neuroscientists want from a new NINDS director
The search is underway for the next director of the U.S. National Institute of Neurological Disorders and Stroke, who will face a range of challenges, neuroscientists say, but will also have an “immense opportunity to do good things.”
What neuroscientists want from a new NINDS director
The search is underway for the next director of the U.S. National Institute of Neurological Disorders and Stroke, who will face a range of challenges, neuroscientists say, but will also have an “immense opportunity to do good things.”
By
Helena Kudiabor
15 April 2026 | 4 min read